Top OTC Stories 2013: Switch, Consumer Business Divestment Plans
This article was originally published in The Tan Sheet
The most-read OTC sector stories in “The Tan Sheet” during 2013 include Sanofi’s switch of Nasacort AQ 24HR, an interview with the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Merck and Novartis each pondering the sale of its consumer health unit.
You may also be interested in...
“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position about the potential divestiture of its non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands including Claritin and Coppertone could grow globally with a new owner.
Sanofi Sues FDA To Stop Publication Of Nasacort Labeling Before Launch
After FDA denied Sanofi three years of market exclusivity for OTC Nasacort, the firm filed suit against the agency not to publish the product’s labeling prior to the launch. If successful, the firm could postpone the launch of generic competition.
Sanofi’s Nasacort First-In-Class Switch Receives FDA Approval
The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.